When is GeneDx the better choice?

It is a diagnostic service for rare disease, applying models and expert variant interpretation to exome and genome sequencing where the measure is diagnostic yield. For a paediatric or rare disease programme, interpretation depth is the product rather than the sequencing itself. The clinical purpose is narrow and clear, which makes the performance question answerable rather than diffuse.

When is Tempus the better choice?

The provider software is the indexed product rather than the laboratory, so a health system buys decision support and physician tooling rather than a test result. The health privacy disclosure is the most complete in this category, earned by documenting both the laboratory role and the software role. Oncology decision support flags patients drifting off guideline care, which is a different job from returning a variant report.

GeneDx vs Tempus

Last VerifiedAugust 4, 2026

Verdict

Both run laboratories and sell software on top, and they are pointed at different patients. GeneDx is rare disease diagnosis, applying AI and expert variant interpretation to exome and genome sequencing, measured on how many previously undiagnosed patients get an answer. Tempus is indexed here for the provider software rather than the laboratory: oncology decision support that flags patients drifting off guideline care, physician tooling, and the most complete health privacy disclosure in this category. A paediatric or rare disease service buys GeneDx. An oncology programme buys Tempus. The question neither answers, and the one that should be put to both, is diagnostic yield by ancestry, because reference databases skew European and uncertain results fall disproportionately on everyone else.

Select GeneDx if

It is a diagnostic service for rare disease, applying models and expert variant interpretation to exome and genome sequencing where the measure is diagnostic yield.
For a paediatric or rare disease programme, interpretation depth is the product rather than the sequencing itself.
The clinical purpose is narrow and clear, which makes the performance question answerable rather than diffuse.

Select Tempus if

The provider software is the indexed product rather than the laboratory, so a health system buys decision support and physician tooling rather than a test result.
The health privacy disclosure is the most complete in this category, earned by documenting both the laboratory role and the software role.
Oncology decision support flags patients drifting off guideline care, which is a different job from returning a variant report.

Attribute Matrix

Side by Side

Axis	G GeneDx	T Tempus
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.

Caris Life Sciences vs Tempus→GeneDx vs SOPHiA GENETICS→Helix vs Tempus→AccurKardia vs Ceribell→AccurKardia vs Eko Health→AccurKardia vs HeartSciences→

Disclosure

Both companies operate their own laboratories and sell software built on the data those laboratories generate, so the same organisation orders the analysis, produces the result and reports the performance. The shared unaddressed exposure is ancestral representation: reference databases and published variant evidence skew heavily European, so variants of uncertain significance return more often for everyone else, and neither publishes yield or interpretation performance by ancestry. Genomic data is permanent, cannot be revoked once disclosed and implicates biological relatives who never consented.